Extremely Low Risk of HCC Development in Patients With Chronic Hepatitis B in Immune-Tolerant Phase
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Alimentary Pharmacology & Therapeutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Extremely Low Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B in Immune-Tolerant Phase
Aliment. Pharmacol. Ther. 2020 Jul 01;52(1)196-204, HA Lee, HW Lee, IH Kim, SY Park, DH Sinn, JH Yu, YS Seo, SH Um, JI Lee, KS Lee, CH Lee, WY Tak, YO Kweon, W Kang, YH Paik, JW Lee, SJ Suh, YK Jung, BK Kim, JY Park, DY Kim, SH Ahn, KH Han, HJ Yim, SU KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.